Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
eXoZymes Inc. - Common Stock
(NQ:
EXOZ
)
5.770
+0.010 (+0.17%)
Delayed Quote
Updated: 3:27 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about eXoZymes Inc. - Common Stock
< Previous
1
2
Next >
Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
Today 11:45 EDT
October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, “Converting Cell-Free...
Via
TheNewswire.com
Topics
Initial Public Offering
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
September 08, 2026
Program expected to commence in Q4 2026 and establish a roadmap for larger-scale production in 2027
From
eXoZymes
Via
ACCESS Newswire
Investor Summit | MicroCap Opportunities to Watch - August 26
August 24, 2026
From
Investor Summit Group
Via
ACCESS Newswire
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
August 20, 2026
From
eXoZymes
Via
ACCESS Newswire
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
August 18, 2026
From
eXoZymes
Via
ACCESS Newswire
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
March 31, 2026
Via
ACCESS Newswire
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
August 11, 2026
From
eXoZymes
Via
ACCESS Newswire
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
July 23, 2026
From
eXoZymes
Via
ACCESS Newswire
Q2 Virtual Investor Summit Presentations Now Available On Demand
June 30, 2026
From
Investor Summit Group
Via
ACCESS Newswire
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
June 24, 2026
From
eXoZymes
Via
ACCESS Newswire
eXoZymes Inc. Announces Closing of $6 Million Public Offering
June 17, 2026
From
eXoZymes
Via
ACCESS Newswire
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
June 08, 2026
Via
ACCESS Newswire
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
May 07, 2026
Via
ACCESS Newswire
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
April 10, 2026
Via
ACCESS Newswire
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
March 25, 2026
Via
ACCESS Newswire
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
March 18, 2026
Via
ACCESS Newswire
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
March 12, 2026
Via
ACCESS Newswire
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
February 10, 2026
Via
ACCESS Newswire
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
January 29, 2026
Via
ACCESS Newswire
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
December 11, 2025
Via
ACCESS Newswire
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
November 13, 2025
Via
ACCESS Newswire
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
November 13, 2025
Via
ACCESS Newswire
eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST
November 10, 2025
Via
ACCESS Newswire
CEO of eXoZymes on 'AI in Life Sciences' panel at the Beryl Elites' Investment Conference
October 30, 2025
Via
ACCESS Newswire
CEO of eXoZymes to Present at Spartan Capital Securities' Second Annual Investor Conference
October 29, 2025
Via
ACCESS Newswire
CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference
October 23, 2025
Via
ACCESS Newswire
Driving the Cell-Free Revolution: eXoZymes Leaders Join BioMADE Leadership & Technical Committees
September 30, 2025
Via
ACCESS Newswire
eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today
August 12, 2025
Via
ACCESS Newswire
eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST
August 07, 2025
Via
ACCESS Newswire
eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity
July 29, 2025
Via
ACCESS Newswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
